222 related articles for article (PubMed ID: 31114386)
1. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease.
Bergamasco A; Hartmann N; Wallace L; Verpillat P
Clin Epidemiol; 2019; 11():257-273. PubMed ID: 31114386
[No Abstract] [Full Text] [Related]
2. Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review.
Hoffmann-Vold AM; Maher TM; Philpot EE; Ashrafzadeh A; Distler O
ERJ Open Res; 2021 Jan; 7(1):. PubMed ID: 33644224
[TBL] [Abstract][Full Text] [Related]
3. Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis.
Bairkdar M; Rossides M; Westerlind H; Hesselstrand R; Arkema EV; Holmqvist M
Rheumatology (Oxford); 2021 Jul; 60(7):3121-3133. PubMed ID: 33630060
[TBL] [Abstract][Full Text] [Related]
4. Autologous stem cell transplantation in a patient with systemic sclerosis-associated interstitial lung disease in Taiwan.
Pan YJ; Huang WH; Su KY
Asian Pac J Allergy Immunol; 2021 Sep; ():. PubMed ID: 34542301
[TBL] [Abstract][Full Text] [Related]
5. Prevalence, incidence, and survival analysis of interstitial lung diseases in Hong Kong: a 16-year population-based cohort study.
Ye Y; Sing CW; Hubbard R; Lam DCL; Li HL; Li GH; Ho SC; Cheung CL
Lancet Reg Health West Pac; 2024 Jan; 42():100871. PubMed ID: 38357389
[TBL] [Abstract][Full Text] [Related]
6. Systemic sclerosis, silica exposure and cellular therapies: The sand in the gears?
Lescoat A; Rimar D; Farge D
Rev Med Interne; 2024 Feb; ():. PubMed ID: 38395716
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Sexual Dysfunction in People With Systemic Sclerosis and the Associated Risk Factors: A Systematic Review.
Gao R; Qing P; Sun X; Zeng X; Hu X; Zhang S; Yang Y; Qin L
Sex Med; 2021 Aug; 9(4):100392. PubMed ID: 34280592
[TBL] [Abstract][Full Text] [Related]
8. Systemic sclerosis-associated interstitial lung disease.
Perelas A; Silver RM; Arrossi AV; Highland KB
Lancet Respir Med; 2020 Mar; 8(3):304-320. PubMed ID: 32113575
[TBL] [Abstract][Full Text] [Related]
9. Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States.
Fan Y; Bender S; Shi W; Zoz D
J Manag Care Spec Pharm; 2020 Dec; 26(12):1539-1547. PubMed ID: 32996805
[TBL] [Abstract][Full Text] [Related]
10. Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.
Khanna D; Tashkin DP; Denton CP; Renzoni EA; Desai SR; Varga J
Am J Respir Crit Care Med; 2020 Mar; 201(6):650-660. PubMed ID: 31841044
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Khanna D; Lin CJF; Furst DE; Goldin J; Kim G; Kuwana M; Allanore Y; Matucci-Cerinic M; Distler O; Shima Y; van Laar JM; Spotswood H; Wagner B; Siegel J; Jahreis A; Denton CP;
Lancet Respir Med; 2020 Oct; 8(10):963-974. PubMed ID: 32866440
[TBL] [Abstract][Full Text] [Related]
12. Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview.
Mackintosh JA; Stainer A; Barnett JL; Renzoni EA
Semin Respir Crit Care Med; 2019 Apr; 40(2):208-226. PubMed ID: 31137061
[TBL] [Abstract][Full Text] [Related]
13. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.
Hoffmann-Vold AM; Allanore Y; Alves M; Brunborg C; Airó P; Ananieva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Kowal-Bielecka O; Riccardi A; Distler O;
Ann Rheum Dis; 2021 Feb; 80(2):219-227. PubMed ID: 32988845
[TBL] [Abstract][Full Text] [Related]
14. Management of Fibrosing Interstitial Lung Diseases.
Maher TM; Wuyts W
Adv Ther; 2019 Jul; 36(7):1518-1531. PubMed ID: 31119691
[TBL] [Abstract][Full Text] [Related]
15. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Flaherty KR; Wells AU; Cottin V; Devaraj A; Walsh SLF; Inoue Y; Richeldi L; Kolb M; Tetzlaff K; Stowasser S; Coeck C; Clerisme-Beaty E; Rosenstock B; Quaresma M; Haeufel T; Goeldner RG; Schlenker-Herceg R; Brown KK;
N Engl J Med; 2019 Oct; 381(18):1718-1727. PubMed ID: 31566307
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers of skin and lung fibrosis in systemic sclerosis.
Martinović Kaliterna D; Petrić M
Expert Rev Clin Immunol; 2019 Nov; 15(11):1215-1223. PubMed ID: 31539483
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
[TBL] [Abstract][Full Text] [Related]
18. Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management.
Mirsaeidi M; Barletta P; Glassberg MK
Front Med (Lausanne); 2019; 6():248. PubMed ID: 31737640
[TBL] [Abstract][Full Text] [Related]
19. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.
Wijsenbeek M; Kreuter M; Olson A; Fischer A; Bendstrup E; Wells CD; Denton CP; Mounir B; Zouad-Lejour L; Quaresma M; Cottin V
Curr Med Res Opin; 2019 Nov; 35(11):2015-2024. PubMed ID: 31328965
[No Abstract] [Full Text] [Related]
20. Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study.
Li Q; Wallace L; Patnaik P; Alves M; Gahlemann M; Kohlbrenner V; Raabe C; Wang JR; Garry EM
Rheumatology (Oxford); 2021 Apr; 60(4):1915-1925. PubMed ID: 33155024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
